Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Tilray Brands Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Tilray Brands Inc trades at $3.1 (market cap $463.31M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 19.2× Tilray Brands Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| KYMR | TLRY | |
|---|---|---|
Market Cap | $8.88B | $463.31M |
Volume | 1,028,790 | 4,627,093 |
Sector | Health | Health |
52-Week High | $127.31 | $16.80 |
52-Week Low | $55.80 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $8.27B | $617.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $3.27, down 2.68% on the day and near 52-week lows, reflecting persistent bearish pressure. The stock's technical indicators are mixed but overall signal remains negative. Fundamentally, the company reported a net loss of $2.19 billion in 2025 despite $821 million in revenue, with profitability metrics deeply negative. Recent news highlights continued stock weakness and strategic brand expansions under Tilray ownership.
The outlook is highly speculative; TLRY faces significant execution and profitability challenges, though analyst consensus suggests substantial upside potential from current levels. Key risks include ongoing losses, high debt levels, and regulatory uncertainty in the cannabis sector. Investment suitability is limited to high-risk tolerance investors betting on a operational turnaround or favorable regulatory shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
